Opdivo Qvantig™ (nivolumab/hyaluronidase-nvhy) – New formulation approval
December 27, 2024 - The FDA announced the approval of Bristol Myers Squibb’s Opdivo Qvantig (nivolumab/hyaluronidase-nvhy), a subcutaneous (SC) formulation of Opdivo® (nivolumab).
